Thank you for subscribing!
Finfeed Archived May 25, 2021
Initial in vitro studies carried out by Neurotech International Limited (ASX: NTI) in collaboration with the internationally recognised Neurodevelopment in Health and Disease Laboratory at RMIT University to assess the effects of the lead NTI/Dolce strains on key neuro-markets that are used in assessing the onset and progression of Multiple Sclerosis (MS).
Finfeed Archived Aug 11, 2020
Japan is an important market for clinical stage regenerative medicine company, Regeneus Ltd (ASX: RGS), which has just negotiated a license agreement with Kyocera Corporation (Kyocera, TYO:6971) to develop and commercialise Progenza for Knee Osteoarthritis (Progenza OA) in Japan.
Next Investors Archived Mar 02, 2020
Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.
Get expert stock analysis direct in your inbox
Join Our Mailing List
